A5037664174- Renal Transplantation Outcomes and Treatments
- Organ Transplantation Techniques and Outcomes
- Hepatitis C virus research
- Organ Donation and Transplantation
- Liver Disease and Transplantation
- Hepatitis B Virus Studies
- Liver Disease Diagnosis and Treatment
- Transplantation: Methods and Outcomes
- Renal Diseases and Glomerulopathies
- Cytomegalovirus and herpesvirus research
- Pharmacological Effects and Toxicity Studies
- Neurological Complications and Syndromes
- Parvovirus B19 Infection Studies
- Renal and Vascular Pathologies
- Hormonal Regulation and Hypertension
- HIV/AIDS drug development and treatment
- Organ and Tissue Transplantation Research
- COVID-19 Clinical Research Studies
- Mast cells and histamine
- Polyomavirus and related diseases
- Pregnancy and Medication Impact
- Receptor Mechanisms and Signaling
- Parathyroid Disorders and Treatments
- COVID-19 Impact on Reproduction
- Amyloidosis: Diagnosis, Treatment, Outcomes
Hospital Clínic de Barcelona
2015-2025
Universitat de Barcelona
2008-2024
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2000-2024
Fundació Clínic per a la Recerca Biomèdica
2021-2022
Barcelona Institute for Global Health
2018
Instituto de Salud Carlos III
2016
Metabolism and Renal Physiology
2000-2010
Charité - Universitätsmedizin Berlin
2007
Research Institute Hospital 12 de Octubre
2002
Hospital Terrassa
1999
Coronavirus disease 2019 (COVID-19) predisposes patients to bacterial and fungal superinfections due the impairment of immunological system. Among associated opportunistic infections, mucormycosis is one least frequent but with highest mortality. We describe two cases in kidney transplant recipients, while they were hospitalized for SARS-CoV-2 pneumonia, rhinosinusal musculoskeletal involvement, respectively.
We sought to determine the frequency, risk factors, and clinical impact of recurrent urinary tract infections (UTI) in kidney transplant recipients. Of 867 patients who received a between 2003 2010, 174 (20%) presented at least one episode UTI. Fifty-five UTI (32%) 78% them could be also considered relapsing episodes. Recurrent was caused by extended-spectrum betalactamase (ESBL)-producing Klebsiella pneumoniae (31%), followed non-ESBL producing Escherichia coli (15%), multidrug-resistant...
C3 glomerulopathy is a rare disease caused by fluid phase dysregulation of the alternative complement pathway. Currently, treatment depends on clinical and histological severity includes nephroprotection, unspecific immunosuppression terminal blockers (C5), without having an etiological approved. has high recurrence rates after kidney transplantation with risk graft loss. Fortunately, new molecules are being developed that specifically target proximal pathway, such as iptacopan, factor B...
Background. Hepatitis C virus (HCV) infection represents an important problem for the dialysis population due to its high prevalence and long-term development of chronic liver disease, particularly following renal transplantation.
Genetically defined deficiencies in key components of the innate immune system have been associated with a greater risk infection. The aim this study was to assess influence genetic variability receptors (mannose-binding lectin [MBL], mannose-associated serine-protease-2 [MASP-2], and Toll-like [TLR4]) infections after kidney transplantation.All patients undergoing or kidney-pancreas transplantation during 3-year period were included. Functionally relevant mutations MBL2, MASP2, TLR4 genes...
Pancreas graft status in simultaneous pancreas-kidney transplant (SPKTx) is currently assessed by nonspecific biochemical markers, typically amylase or lipase. Identifying a noninvasive biomarker with good sensitivity detecting early pancreas rejection could improve SPKTx management.Here, we developed pilot study to explore donor-derived cell-free DNA (dd-cfDNA) performance predicting biopsy-proven acute (P-BPAR) of the cohort 36 recipients biopsy-matched plasma samples. dd-cfDNA was...
Ischemia-reperfusion injury (IRI) upon transplantation is one of the most impactful events that kidney graft suffers during its life. Its clinical manifestation in recipient, delayed function (DGF), has serious prognostic consequences. However, different definitions DGF are subject to physicians' choices and centers' policies, a more objective tool quantify IRI needed. Here, we propose use donor-derived cell-free DNA (ddcfDNA) for this scope.
In an overwhelming demand scenario, such as the SARS-CoV-2 pandemic, pressure over health systems may outburst their predicted capacity to deal with extreme situations. Therefore, in order successfully face a emergency, scientific evidence and validated models are needed provide real-time information that could be applied by any center, especially for high-risk populations, transplant recipients. We have developed hybrid prediction model whose accuracy relative several alternative...
The introduction of donor-derived free DNA (ddcfDNA) has emerged as an accurate non-invasive biomarker to diagnose rejection, compared classical ones. Here we evaluate our experience after its implementation in center in-house technique. Single-center cross-sectional study with extraction cell-free blood and quantification the ddcfDNA using AlloSeqcfDNA assay (CareDx) at time performing biopsies 'per protocol' or indication' between December 2020 2023. 172 graft were included (59 for...
Background. The contribution of mammalian target rapamycin (mTOR) inhibitors to proteinuria is controversial. aim was analyse in suboptimal kidney calcineurin inhibitor-(CNI) free de novo immunosuppression.
The increase in the prevalence of end-stage renal disease developed countries and shortage deceased donors has made it necessary to graft pool by means several strategies, such as live donation, non-heart-beating donors, expanded criteria donors. Frequently, because increasing acceptance older we find a higher percentage incidental masses these result inherent epidemiology this disease. These kidneys can be considered suitable grafts after bench surgery remove tumor.Retrospective analysis...
Anemia is highly prevalent in end-stage chronic kidney disease patients, increasing their risk of receiving blood transfusions during and on the days after a transplant (KTx) surgery. However, there currently lack data that thoroughly describes this phenomenon population, associated factors, how they could benefit from application Patient Blood Management (PBM) guidelines.